Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings and Scrutinizer Report of 12th Annual General Meeting is attached26-09-2023
26-09-2023
Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd26-09-2023
Glenmark Life Sciences Ltd - 543322 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September 25, 2023 for Glenmark Pharmaceuticals Ltd26-09-2023
Glenmark Life Sciences Ltd - 543322 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 25, 2023 for Glenmark Pharmaceuticals Ltd26-09-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Credit Rating
India Ratings has discontinued and withdrawal the outstanding voluntary issuer rating disclosure due to regulatory requirements.23-09-2023
GLS acquisition propels Nirma's pharma business into next phase of growth, says MD Hiren Patel
The acquisition of Glenmark Life Sciences will see Nirma foray into the Active Pharmaceutical Ingredient segment22-09-2023
Glenmark Life Sciences Ltd - 543322 - Public Announcement - Open Offer
DAM Capital Advisors Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement under Regulations 3(1) and 4 read with Regulations 13, 14 and 15(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, for the attention of the Public Shareholders of Glenmark Life Sciences Ltd ("Target Company").21-09-2023
Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs 5,652 crore
Glenmark Pharma will own 7.84% in GLS after the divestment; pursuant to the transaction, Nirma Limited will make a mandatory open offer to all public shareholders of GLS21-09-2023
Glenmark Life Sciences Ltd - 543322 - Board Meeting Outcome for Outcome Of The Board Meeting Held On September 21, 2023
Disclosure pursuant to the provisions of Regulation 30 of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 201521-09-2023